Thalidomide has shown efficacy in the treatment of advanced refractory multiple myeloma even after autologous stem-cell transplantation [1] and has been evaluated alone or in combination in the treatment of various solid and hematological malignancies [2–4]. Both antiangiogenic activity [5] and the immunomodulatory properties of thalidomide are proposed mechanisms for its beneficial effects [6]. Common side-effects during treatment with thalidomide are sedation, constipation, skin rash and peripheral neuropathy.
No takes yet. Share an insight, caveat, or question.
Trojan et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: